查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1620832

再生醫學市場：按類型、應用分類 - 2025-2030 年全球預測

Regenerative Medicine Market by Type (Cell-Based Immunotherapy & Cell Therapy Products, Gene Therapy Products, Small Molecule & Biologic), Application (Cardiovascular, Diabetes, Musculoskeletal Disorders) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年再生醫學市場價值為230.2億美元，預計2024年將達到283.5億美元，複合年成長率為23.76%，到2030年將達到1024億美元。

再生醫學是一個變革性的醫療保健領域，專注於利用幹細胞療法、組織工程和基因編輯等技術來修復、替換和再生受損的組織和器官。這種需求源自於慢性病的增加、人口老化以及傳統醫學治療的限制。應用範圍廣泛，包括整形外科、皮膚科、心臟科和神經病學。最終用途領域從醫院和診所到研究機構和生技公司，凸顯了市場潛力的廣泛性。市場成長受到多種因素的影響，包括生物技術和材料科學的進步、政府和私人資金的增加以及再生療法意識的增強。潛在的商機在於未開發的新興市場、持續的研發以及主要企業之間的策略聯盟。

主要市場統計
基準年[2023] 230.2億美元
預測年份 [2024] 283.5億美元
預測年份 [2030] 1024億美元
複合年成長率（%） 23.76%

然而，這個市場也存在局限性和挑戰，包括不斷上升的治療成本、嚴格的法律規範、圍繞幹細胞使用的倫理問題以及擴大生產的技術障礙。也存在治療方法標準化、治療效果延長等問題。為了推動業務成長，在開發具有成本效益的生物加工技術、利用人工智慧和機器學習進行個人化醫療以及增強組織工程的支架材料方面存在創新機會。此外，專注於非侵入性再生治療並創建用於治療監測的可靠生物標記也可能是一條有利的途徑。

競爭格局正在迅速變化，需要不斷的創新和策略遠見。公司應該透過投資跨學科合作和夥伴關係以及交叉傳播思想和技術來保持創新曲線的領先地位。由於技術創新和解決未滿足的需求的雙重力量，該市場有望大幅擴張。如果我們能夠明智地管理這些複雜的動態，我們相信我們將能夠在市場上建立牢固的地位，並為全球醫療保健的發展做出重大貢獻。

市場動態：揭示快速發展的再生醫學市場的關鍵市場洞察

供需的動態交互作用正在改變再生醫學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 擴大幹細胞技術、基因治療和組織工程的應用
    • 政府研究投入增加
    • 私人公司的產品核可和研發活動的活性化
  • 市場限制因素
    • 與幹細胞和再生醫學相關的高成本和監管問題
  • 市場機會
    • 再生醫學生技藥品的技術進步
    • 對器官和骨移植的需求不斷增加
  • 市場挑戰
    • 有關在研究和開發中使用胚胎幹細胞的倫理問題

波特五力：駕馭再生醫學市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解再生醫學市場的外部影響

外部宏觀環境因素在塑造再生醫學市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解再生醫學市場的競爭狀況

對再生醫學市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣再生醫學市場供應商績效評估

FPNV定位矩陣是評估再生醫學市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了再生醫學市場的成功之路

再生醫學市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 更多採用幹細胞技術、基因治療和組織工程
      • 政府加大對再生醫學研究的投資
      • 產品核可以及私人公司研發活動的增加
    • 抑制因素
      • 與幹細胞和再生醫學相關的高成本和監管問題
    • 機會
      • 再生醫學生技藥品的技術進步
      • 對器官和骨移植的需求增加
    • 任務
      • 有關在研究和開發中使用胚胎幹細胞的倫理問題
  • 市場區隔分析
    • 類型：細胞免疫療法和細胞治療產品在個人化治療中的重要應用
    • 應用：再生醫學在心血管疾病的重要性日益增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章再生醫學市場：依類型

  • 基於細胞的免疫療法和細胞治療產品
    • 同類產品
    • 自製產品
  • 基因治療產品
  • 小分子/生技藥品
  • 組織工程產品

第7章再生醫學市場：依應用分類

  • 心血管
  • 糖尿病
  • 肌肉骨骼疾病
  • 眼科疾病
  • 腫瘤學
  • 創傷護理

第8章 北美和南美再生醫學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區再生醫學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東、非洲再生醫學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 4DMT 的 4D-150 獲得 FDA 的高級治療指定，這是一種用於玻璃體內治療濕性 AMD 的基因藥物。
    • Sysmex 和 JCR Pharma 的合資企業 Allied Cell 收購了一條新的管道，以促進再生醫療產品的早期社會實施
    • 西乃山建立再生醫學研究所
  • 戰略分析和建議

公司名單

  • 4D Molecular Therapeutics, Inc.
  • Allergan PLC
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • Bayer AG
  • CMIC HOLDINGS Co., LTD.
  • Editas Medicine, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Gilead Sciences, Inc.
  • Integra LifeSciences Holdings Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Medtronic PLC
  • Mimedx Group
  • Novartis AG
  • Organogenesis Inc.
  • Osiris Therapeutics, Inc. by Smith & Nephew PLC
  • REPROCELL Inc.
  • SanBio Company Limited
  • Sartorius AG
  • Sumitomo Pharma Co., Ltd.
  • Sysmex Corporation
  • Takeda Pharmaceutical Co. Ltd.
  • Tenaya Therapeutics, Inc.
  • Vericel Corporation
  • Wright Medical Group NV
  • Zimmer Biomet Holdings Inc.
Product Code: MRR-430D42AA0F5B

The Regenerative Medicine Market was valued at USD 23.02 billion in 2023, expected to reach USD 28.35 billion in 2024, and is projected to grow at a CAGR of 23.76%, to USD 102.40 billion by 2030.

Regenerative medicine is a transformative healthcare arena focused on repairing, replacing, or regenerating damaged tissues and organs using techniques like stem cell therapy, tissue engineering, and gene editing. Its necessity arises from the increasing prevalence of chronic diseases, aging populations, and the limitations of conventional medical therapies. Applications are vast, spanning orthopedics, dermatology, cardiology, and neurology, among others. End-use sectors range from hospitals and clinics to research institutions and biotech companies, highlighting its broad market potential. The market growth is influenced by several factors: advancements in biotechnology and material science, an increase in government and private funding, and rising awareness about regenerative treatments. Potential opportunities lie in untapped emerging markets, continual R&D, and strategic collaborations among key industry players.

KEY MARKET STATISTICS
Base Year [2023] USD 23.02 billion
Estimated Year [2024] USD 28.35 billion
Forecast Year [2030] USD 102.40 billion
CAGR (%) 23.76%

However, limitations and challenges in this market include high costs of treatment, stringent regulatory frameworks, ethical concerns associated with stem cell use, and technical hurdles in scaling production. The sector also faces challenges related to the standardization of therapies and the long-time horizon for treatment efficacy. To foster business growth, innovation opportunities exist in developing cost-effective bioprocessing techniques, leveraging AI and machine learning for personalized medicine, and enhancing scaffolding materials for tissue engineering. Additionally, focusing on non-invasive regenerative therapies and creating reliable biomarkers for treatment monitoring could present lucrative avenues.

The regenerative medicine market is characterized by intense research and a rapidly evolving competitive landscape, necessitating constant technological advancements and strategic foresight. Companies should invest in interdisciplinary collaborations and partnerships to cross-pollinate ideas and technologies, thereby staying ahead in the innovation curve. This market is poised for significant expansion, driven by the dual forces of innovation and the unmet clinical needs it seeks to address. Those navigating these intricate dynamics wisely are likely to achieve robust market positions and contribute meaningfully to the advancement of global healthcare.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Regenerative Medicine Market

The Regenerative Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of stem cell technologies, gene therapies, and tissue engineering
    • Rising government investments in regenerative medicine research
    • Product approval coupled with increasing R&D activities by private players
  • Market Restraints
    • High cost and regulatory issues pertaining to stem cell and regenerative medicine
  • Market Opportunities
    • Technological advancements in regenerative medicine biologics
    • Growing demand for organ transplantation and bone grafting
  • Market Challenges
    • Ethical issues related to the use of embryonic stem cells in R&D

Porter's Five Forces: A Strategic Tool for Navigating the Regenerative Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Regenerative Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Regenerative Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Regenerative Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Regenerative Medicine Market

A detailed market share analysis in the Regenerative Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Regenerative Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Regenerative Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Regenerative Medicine Market

A strategic analysis of the Regenerative Medicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Regenerative Medicine Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Allergan PLC, Amgen Inc., Astellas Pharma Inc., Athersys, Inc., Bayer AG, CMIC HOLDINGS Co., LTD., Editas Medicine, Inc., FUJIFILM Cellular Dynamics, Inc., Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, JCR Pharmaceuticals Co., Ltd., Medtronic PLC, Mimedx Group, Novartis AG, Organogenesis Inc., Osiris Therapeutics, Inc. by Smith & Nephew PLC, REPROCELL Inc., SanBio Company Limited, Sartorius AG, Sumitomo Pharma Co., Ltd., Sysmex Corporation, Takeda Pharmaceutical Co. Ltd., Tenaya Therapeutics, Inc., Vericel Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings Inc..

Market Segmentation & Coverage

This research report categorizes the Regenerative Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cell-Based Immunotherapy & Cell Therapy Products, Gene Therapy Products, Small Molecule & Biologic, and Tissue-Engineered Products. The Cell-Based Immunotherapy & Cell Therapy Products is further studied across Allogeneic Products and Autologous Products.
  • Based on Application, market is studied across Cardiovascular, Diabetes, Musculoskeletal Disorders, Ocular Disorders, Oncology, and Wound Care.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of stem cell technologies, gene therapies, and tissue engineering
      • 5.1.1.2. Rising government investments in regenerative medicine research
      • 5.1.1.3. Product approval coupled with increasing R&D activities by private players
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and regulatory issues pertaining to stem cell and regenerative medicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in regenerative medicine biologics
      • 5.1.3.2. Growing demand for organ transplantation and bone grafting
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues related to the use of embryonic stem cells in R&D
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Significant applications of cell-based immunotherapies and cell therapy products in personalized treatment
    • 5.2.2. Application: Growing significance of regenerative medicines for cardiovascular diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Regenerative Medicine Market, by Type

  • 6.1. Introduction
  • 6.2. Cell-Based Immunotherapy & Cell Therapy Products
    • 6.2.1. Allogeneic Products
    • 6.2.2. Autologous Products
  • 6.3. Gene Therapy Products
  • 6.4. Small Molecule & Biologic
  • 6.5. Tissue-Engineered Products

7. Regenerative Medicine Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular
  • 7.3. Diabetes
  • 7.4. Musculoskeletal Disorders
  • 7.5. Ocular Disorders
  • 7.6. Oncology
  • 7.7. Wound Care

8. Americas Regenerative Medicine Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Regenerative Medicine Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Regenerative Medicine Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. 4DMT Receives FDA Regenerative Medicine Advanced Therapy Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD
    • 11.3.2. AlliedCel, a Joint Venture Between Sysmex and JCR Pharmaceuticals, Has Acquired a New Pipeline to Promote the Early Social Implementation of Regenerative Medicine Products
    • 11.3.3. Mount Sinai Launches Institute for Regenerative Medicine
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Molecular Therapeutics, Inc.
  • 2. Allergan PLC
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. Athersys, Inc.
  • 6. Bayer AG
  • 7. CMIC HOLDINGS Co., LTD.
  • 8. Editas Medicine, Inc.
  • 9. FUJIFILM Cellular Dynamics, Inc.
  • 10. Gilead Sciences, Inc.
  • 11. Integra LifeSciences Holdings Corporation
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Medtronic PLC
  • 14. Mimedx Group
  • 15. Novartis AG
  • 16. Organogenesis Inc.
  • 17. Osiris Therapeutics, Inc. by Smith & Nephew PLC
  • 18. REPROCELL Inc.
  • 19. SanBio Company Limited
  • 20. Sartorius AG
  • 21. Sumitomo Pharma Co., Ltd.
  • 22. Sysmex Corporation
  • 23. Takeda Pharmaceutical Co. Ltd.
  • 24. Tenaya Therapeutics, Inc.
  • 25. Vericel Corporation
  • 26. Wright Medical Group N.V.
  • 27. Zimmer Biomet Holdings Inc.

LIST OF FIGURES

  • FIGURE 1. REGENERATIVE MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. REGENERATIVE MEDICINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. REGENERATIVE MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. REGENERATIVE MEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALLOGENEIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AUTOLOGOUS PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SMALL MOLECULE & BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE-ENGINEERED PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY WOUND CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023